Skip to content
OpenCapital
Get started

Replimune Group REPL Business Segments — SG&A

Similar metrics at other companies

Agios Pharmaceuticals logo
AGIOReportable Segment — SG&A
$48.3M+16.3%
Travere Therapeutics, Inc. logo
TVTXReportable Segment — SG&A
$80.25M+32.8%
Zevra Therapeutics, Inc. logo
ZVRAReportable Segment — SG&A
$14.35M+19.8%
Indivior Pharmaceuticals, Inc. logo
INDVReportable Segment — SG&A
$124M-6.8%
Vir Biotechnology, Inc. logo
VIRReportable Segment — SG&A
$23.34M-2.5%
Lucid Group, Inc. logo
LCIDReportable Segment — SG&A
$304.18M+43.4%

Other financials

Income statement

See full
Operating income-$71.9M-8.9%
Net income-$70.9M-6.9%
EPS (diluted)-$0.77+2.5%

Balance sheet

See full
Cash & equivalents$124.7M-28.3%
Total debt$79.2M+0.5%
Total equity$210.5M-56.4%
Total assets$333.6M-44.7%

Cash flow

See full
Operating cash flow-$66.0M-30.1%
CapEx$135.0K-92.5%
Free cash flow-$66.1M-25.9%

Valuation

See full
Market cap$814.27M+230%
Enterprise value$768.82M+239%

Returns & leverage

See full
Return on equity-90.9%+362pp
Debt / equity0.4×+0.2×
Current ratio5.6×-5.8×

Where this comes from

Reported directly by Replimune Group in its filing.

Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.

The official record: Replimune Group’s 10-Q, filed February 3, 2026, on SEC EDGAR. View the filing →

Ask your AI about Replimune Group's business segments — sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Replimune Group's business segments — SG&A?
Replimune Group (REPL) reported business segments — SG&A of $18.73M in Q4 2025.
How has Replimune Group's business segments — SG&A changed year-over-year?
Replimune Group's business segments — SG&A increased by 4.0% year-over-year, from $18.02M to $18.73M.
What does business segments — SG&A mean?
Includes all non-research operating costs, such as corporate overhead, legal, administrative salaries, and business development expenses. This metric measures the company's operational efficiency and the cost of maintaining the corporate infrastructure required to support clinical-stage operations.